NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer
Advanced Science · 2026-06 · 13 (36)
DOI: 10.1002/advs.202523605 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.04.2026. Verfasst von Bin Guo und 20 weiteren Autor:innen. Beteiligte Einrichtung: China National Center for Bioinformation, Beijing, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Anoikis, NAD(P)H Dehydrogenase (Quinone), Immune Evasion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National High Level Hospital Clinical Research Funding (High Quality Clinical Research Project of Peking University First Hospital), National Natural Science Foundation of China.
Abstract (Originalsprache)
T1 high‐grade (T1HG) bladder cancer represents an aggressive subset of non–muscle‐invasive bladder cancer (NMIBC) with frequent Bacillus Calmette–Guérin (BCG) failure and a high risk of progression, yet current models inadequately guide treatment selection between early cystectomy and bladder preservation. Integrative multi‐omics profiling of 147 tumors identifies two clinically distinct subtypes. A high‐risk subtype (T1HG1) is defined by coupled anoikis resistance and immune evasion, exhibiting markedly increased progression rates (>80% vs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- China National Center for Bioinformation, Beijing, China.
- Senior Department of Urology, Chinese PLA General Hospital, Beijing, China.
- Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Department of Urology, Peking University First Hospital, Beijing, China.
- Institute of Urology, Peking University, Beijing, China.
ORCID-Profile: Weimin Ci
Förderung
- National Key R&D Program of China
- National High Level Hospital Clinical Research Funding (High Quality Clinical Research Project of Peking University First Hospital)
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Guo, B., Xu, C., Fu, S., Cheng, Q., Li, J., Shang, L., Li, G., Yang, Y., Wang, Y., Gong, Y., Xiong, S., Fan, J., Yuan, C., Zhang, M., Zuo, Y., Papaleo, E., Shi, Y., Liang, Y., Li, X., …, & Ci, W. (2026). NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer. Advanced Science, 13(36). https://doi.org/10.1002/advs.202523605
Vancouver
Guo B, Xu C, Fu S, Cheng Q, Li J, Shang L, et al. NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer. Advanced Science. 2026;13(36). doi:10.1002/advs.202523605
BibTeX
@article{Guo2026,
author = {Guo, Bin and Xu, Chunru and Fu, Shufan and Cheng, Qiang and Li, Juan and Shang, Linkuo and Li, Gaojie and Yang, Yang and Wang, Ying and Gong, Yanqing and Xiong, Shengwei and Fan, Jian and Yuan, Changwei and Zhang, Mei and Zuo, Yifan and Papaleo, Elena and Shi, Yue and Liang, Yuan and Li, Xuesong and Li, Hongzhao and Ci, Weimin},
title = {NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {36},
doi = {10.1002/advs.202523605}
}
EUVIMED